
|Videos|June 10, 2015
Nivolumab Effective in Advanced Non-Squamous NSCLC
Author(s)Luis Paz-Ares, MD
In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Advertisement
In this video, Luis Paz-Ares, MD, discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), with the largest improvement seen in PD-L1-positive patients.
The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
3
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC
4
IMNN-001 Plus Neoadjuvant Chemo Improves OS in Advanced Ovarian Cancer
5





















































